Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Ritonavir-boosted protease inhibitors, Part 2: cardiac implications of lipid alterations.

Cohen CJ.

AIDS Read. 2005 Oct;15(10):528-32, 537-8. Review.

PMID:
16265768
2.
3.

Atazanavir/ritonavir: a review of its use in HIV therapy.

von Hentig N.

Drugs Today (Barc). 2008 Feb;44(2):103-32. doi: 10.1358/dot.2008.44.2.1137107. Review.

PMID:
18389089
4.

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.

Calza L, Manfredi R, Chiodo F.

J Antimicrob Chemother. 2004 Jan;53(1):10-4. Review.

5.

Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.

Youle M.

J Antimicrob Chemother. 2007 Dec;60(6):1195-205. Review.

6.

Lopinavir/ritonavir: appraisal of its use in HIV therapy.

von Hentig N.

Drugs Today (Barc). 2007 Apr;43(4):221-47. Review.

PMID:
17460785
7.

Double-boosted protease inhibitor antiretroviral regimens: what role?

Ribera E, Curran A.

Drugs. 2008;68(16):2257-67. doi: 10.2165/0003495-200868160-00001. Review.

PMID:
18973392
8.

Fosamprenavir calcium plus ritonavir for HIV infection.

Torres HA, Arduino RC.

Expert Rev Anti Infect Ther. 2007 Jun;5(3):349-63. Review.

PMID:
17547501
9.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Oldfield V, Plosker GL.

Drugs. 2006;66(9):1275-99. Review.

PMID:
16827606
10.

HIV protease inhibitors and dyslipidemia.

Clotet B, Negredo E.

AIDS Rev. 2003 Jan-Mar;5(1):19-24. Review.

PMID:
12875104
11.

Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection.

Sahali S, Chaix ML, Delfraissy JF, Ghosn J.

AIDS Rev. 2008 Jan-Mar;10(1):4-14. Review.

PMID:
18385776
12.

The effects of HIV protease inhibitors on carbohydrate and lipid metabolism.

Lee GA, Rao MN, Grunfeld C.

Curr HIV/AIDS Rep. 2005 Feb;2(1):39-50. Review.

PMID:
16091248
13.

Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: report of four cases and review.

Duong M, Buisson M, Cottin Y, Piroth L, Lhuillier I, Grappin M, Chavanet P, Wolff JE, Portier H.

Clin Cardiol. 2001 Oct;24(10):690-4. Review.

14.
15.

[Metabolic disturbances associated with HAART].

Olczak A.

Przegl Epidemiol. 2007;61(4):639-46. Review. Polish.

PMID:
18572495
16.

Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.

Barragan P, Podzamczer D.

Expert Opin Pharmacother. 2008 Sep;9(13):2363-75. doi: 10.1517/14656566.9.13.2363 . Review.

PMID:
18710360
17.

[Therapeutic strategies for HIV infection: tolerance to boost antiproteases].

Viard JP.

Med Mal Infect. 2004 Nov;34 Suppl 3:S209-15. Review. French.

PMID:
15906444
18.

Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia.

Kannel WB, Giordano M.

Am J Cardiol. 2004 Oct 1;94(7):901-6. Review.

PMID:
15464673
19.

Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients.

Umeh OC, Currier JS.

Curr HIV/AIDS Rep. 2005 Aug;2(3):132-9. Review.

PMID:
16091260
20.

Saquinavir/Ritonavir: its evolution and current treatment role.

O'Brien WA 3rd.

AIDS Read. 2006 Jan;16(1):38-44; discussion 43. Review.

PMID:
16433471
Items per page

Supplemental Content

Support Center